This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
Real-own experience with KESIMPTA®▼ (ofatumumab) at the National Hospital
KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1
Please refer to the Summary of Product Characteristics for full safety information, and the safety profile page here.
Watch Dr Wallace Brownlee from Queen Square discuss his first-hand experience with KESIMPTA in the short video below.
‘We first started using the medication (KESIMPTA) in our centre in August 2021, and since then we’ve initiated over 1000 patients with KESIMPTA. I’ll be running through our real-world evidence of the efficacy and safety profile of the medication in this cohort of 1000 patients to date. I think this is a good opportunity for us to review our real-world experience with the use of this medication to better understand the efficacy and safety profile in the UK population.’
Dr Wallace Brownlee
Consultant Neurologist & Clinical Lead for multiple sclerosis, Queen Square
VIDEO
See the efficacy data and discover what KESIMPTA could offer your eligible patients with RMS
RMS, relapsing multiple sclerosis.
Reference
KESIMPTA (ofatumumab) Summary of Product Characteristics.
UK | October 2025 | FA-11498945
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.